ECSP099087A - 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 - Google Patents
2-fenilindoles como antagonistas del receptor de la prostaglandina d2Info
- Publication number
- ECSP099087A ECSP099087A EC2009009087A ECSP099087A ECSP099087A EC SP099087 A ECSP099087 A EC SP099087A EC 2009009087 A EC2009009087 A EC 2009009087A EC SP099087 A ECSP099087 A EC SP099087A EC SP099087 A ECSP099087 A EC SP099087A
- Authority
- EC
- Ecuador
- Prior art keywords
- diseases
- allergic
- inflammation
- itching
- atopic dermatitis
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 208000003251 Pruritus Diseases 0.000 abstract 2
- 208000024780 Urticaria Diseases 0.000 abstract 2
- 201000008937 atopic dermatitis Diseases 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 230000007803 itching Effects 0.000 abstract 2
- KLLLJCACIRKBDT-UHFFFAOYSA-N 2-phenyl-1H-indole Chemical class N1C2=CC=CC=C2C=C1C1=CC=CC=C1 KLLLJCACIRKBDT-UHFFFAOYSA-N 0.000 abstract 1
- 206010002199 Anaphylactic shock Diseases 0.000 abstract 1
- 206010006482 Bronchospasm Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract 1
- 206010016946 Food allergy Diseases 0.000 abstract 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 abstract 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 abstract 1
- 208000011623 Obstructive Lung disease Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 206010038848 Retinal detachment Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 201000008736 Systemic mastocytosis Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 230000007885 bronchoconstriction Effects 0.000 abstract 1
- -1 but not limited to Chemical compound 0.000 abstract 1
- 230000020411 cell activation Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000020932 food allergy Nutrition 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000008423 pleurisy Diseases 0.000 abstract 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 abstract 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 abstract 1
- 230000004264 retinal detachment Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 238000006748 scratching Methods 0.000 abstract 1
- 230000002393 scratching effect Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de 2-fenil-indol, a su preparación, a composiciones farmacéuticas que contienen estos compuestos y a su uso farmacéutico en el tratamiento de un paciente que padece un trastorno mediado por PGD2 incluyendo, pero sin limitación, enfermedades alérgicas (tales como rinitis alérgica, conjuntivitis alérgica, dermatitis atópica, asma bronquial y alergia alimentaria), mastocitosis sistémica, trastornos acompañados por activación sistémica de mastocitos, choque anafiláctico, broncoconstricción, bronquitis, eccema, urticaria, enfermedades acompañadas por picor (tales como dermatitis atópica y urticaria), enfermedades (tales como cataratas, desprendimiento de retina, inflamación, infección y trastornos del sueño) que se generan de manera secundaria como resultado de una conducta que acompaña al picor (tal como rascarse o golpearse), inflamación, enfermedades pulmonares obstructivas crónicas, lesión de isquemia-reperfusión, accidente cerebrovascular, artritis reumatoide crónica, pleuritis, colitis ulcerosa y similares.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82029906P | 2006-07-25 | 2006-07-25 | |
| US82030106P | 2006-07-25 | 2006-07-25 | |
| US82030206P | 2006-07-25 | 2006-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP099087A true ECSP099087A (es) | 2009-02-27 |
Family
ID=38610820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2009009087A ECSP099087A (es) | 2006-07-25 | 2009-01-23 | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20090176804A1 (es) |
| EP (1) | EP2066628B1 (es) |
| JP (1) | JP2009544721A (es) |
| KR (1) | KR20090039735A (es) |
| AR (1) | AR062051A1 (es) |
| AT (1) | ATE485270T1 (es) |
| AU (1) | AU2007276885A1 (es) |
| BR (1) | BRPI0714554A2 (es) |
| CA (1) | CA2659055A1 (es) |
| CL (1) | CL2007002163A1 (es) |
| CO (1) | CO6190511A2 (es) |
| CR (1) | CR10577A (es) |
| DE (1) | DE602007010010D1 (es) |
| DK (1) | DK2066628T3 (es) |
| EC (1) | ECSP099087A (es) |
| GT (1) | GT200900016A (es) |
| IL (1) | IL196587A0 (es) |
| MA (1) | MA30643B1 (es) |
| MX (1) | MX2009000830A (es) |
| NO (1) | NO20090862L (es) |
| PE (1) | PE20080549A1 (es) |
| PT (1) | PT2066628E (es) |
| TN (1) | TNSN08515A1 (es) |
| TW (1) | TW200821286A (es) |
| WO (1) | WO2008014186A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009072576A1 (ja) * | 2007-12-04 | 2009-06-11 | Sapporo Breweries Limited | 骨形成促進剤 |
| RS52809B (sr) * | 2008-11-17 | 2013-10-31 | F. Hoffmann-La Roche Ag. | Naftilsirćetne kiseline |
| MX2012010820A (es) | 2010-03-22 | 2012-10-10 | Actelion Pharmaceuticals Ltd | Derivados de 3-(heteroaril-amino)-1, 2, 3, 4-tetrahidro-9h-carbazo l y sus uso como moduladores del receptor de prostaglandina d2. |
| WO2012140612A1 (en) | 2011-04-14 | 2012-10-18 | Actelion Pharmaceuticals Ltd | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| EP2912458B1 (en) | 2012-10-24 | 2018-07-18 | NYU Winthrop Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
| JP2015089886A (ja) * | 2013-11-06 | 2015-05-11 | 国立大学法人名古屋大学 | 嵩高い置換基を有する化合物を用いた植物成長調整剤 |
| PH12016501764B1 (en) | 2014-03-17 | 2024-05-17 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| WO2015140701A1 (en) | 2014-03-18 | 2015-09-24 | Actelion Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| WO2017046125A1 (en) | 2015-09-15 | 2017-03-23 | Actelion Pharmaceuticals Ltd | Crystalline forms |
| KR20200109293A (ko) | 2017-09-13 | 2020-09-22 | 프로제너티, 인크. | 자간전증 바이오마커 및 관련된 시스템 및 방법 |
| US11884645B2 (en) | 2018-03-02 | 2024-01-30 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
| US12168653B2 (en) | 2018-03-02 | 2024-12-17 | Inflazome Limited | Sulfonamide derivates as NLRP3 inhibitors |
| EP3759090A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| US11834433B2 (en) | 2018-03-02 | 2023-12-05 | Inflazome Limited | Compounds |
| WO2019166632A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| CN112384497A (zh) | 2018-05-09 | 2021-02-19 | 格卢科克斯生物科技有限公司 | 具有选择性nox抑制活性的新型磺酰胺衍生物 |
| WO2021113710A1 (en) | 2019-12-04 | 2021-06-10 | Progenity, Inc. | Assessment of preeclampsia using assays for free and dissociated placental growth factor |
| CN111333516B (zh) * | 2020-04-14 | 2022-09-06 | 国药集团化学试剂有限公司 | 一种2-氯-5-溴硝基苯的制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2006000016A (es) * | 2005-01-26 | 2006-07-31 | Aventis Pharma Inc | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2. |
-
2007
- 2007-07-20 KR KR1020097001687A patent/KR20090039735A/ko not_active Abandoned
- 2007-07-20 DE DE602007010010T patent/DE602007010010D1/de active Active
- 2007-07-20 WO PCT/US2007/073945 patent/WO2008014186A1/en not_active Ceased
- 2007-07-20 EP EP07799729A patent/EP2066628B1/en active Active
- 2007-07-20 MX MX2009000830A patent/MX2009000830A/es active IP Right Grant
- 2007-07-20 PT PT07799729T patent/PT2066628E/pt unknown
- 2007-07-20 CA CA002659055A patent/CA2659055A1/en not_active Abandoned
- 2007-07-20 DK DK07799729.4T patent/DK2066628T3/da active
- 2007-07-20 BR BRPI0714554-3A patent/BRPI0714554A2/pt not_active IP Right Cessation
- 2007-07-20 JP JP2009521914A patent/JP2009544721A/ja not_active Abandoned
- 2007-07-20 AT AT07799729T patent/ATE485270T1/de active
- 2007-07-20 AU AU2007276885A patent/AU2007276885A1/en not_active Abandoned
- 2007-07-23 PE PE2007000951A patent/PE20080549A1/es not_active Application Discontinuation
- 2007-07-24 AR ARP070103291A patent/AR062051A1/es not_active Application Discontinuation
- 2007-07-24 CL CL200702163A patent/CL2007002163A1/es unknown
- 2007-07-25 TW TW096127005A patent/TW200821286A/zh unknown
-
2008
- 2008-12-12 TN TNP2008000515A patent/TNSN08515A1/en unknown
-
2009
- 2009-01-15 CO CO09002745A patent/CO6190511A2/es not_active Application Discontinuation
- 2009-01-19 IL IL196587A patent/IL196587A0/en unknown
- 2009-01-21 CR CR10577A patent/CR10577A/es not_active Application Discontinuation
- 2009-01-22 US US12/357,725 patent/US20090176804A1/en not_active Abandoned
- 2009-01-23 GT GT200900016A patent/GT200900016A/es unknown
- 2009-01-23 EC EC2009009087A patent/ECSP099087A/es unknown
- 2009-02-13 MA MA31635A patent/MA30643B1/fr unknown
- 2009-02-24 NO NO20090862A patent/NO20090862L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20080549A1 (es) | 2008-06-20 |
| CR10577A (es) | 2009-03-20 |
| WO2008014186A1 (en) | 2008-01-31 |
| PT2066628E (pt) | 2010-12-31 |
| TNSN08515A1 (en) | 2010-04-14 |
| DE602007010010D1 (de) | 2010-12-02 |
| JP2009544721A (ja) | 2009-12-17 |
| CL2007002163A1 (es) | 2008-02-08 |
| EP2066628B1 (en) | 2010-10-20 |
| BRPI0714554A2 (pt) | 2013-05-07 |
| KR20090039735A (ko) | 2009-04-22 |
| IL196587A0 (en) | 2009-11-18 |
| MA30643B1 (fr) | 2009-08-03 |
| CA2659055A1 (en) | 2008-01-31 |
| ATE485270T1 (de) | 2010-11-15 |
| TW200821286A (en) | 2008-05-16 |
| EP2066628A1 (en) | 2009-06-10 |
| MX2009000830A (es) | 2009-02-03 |
| AU2007276885A1 (en) | 2008-01-31 |
| DK2066628T3 (da) | 2011-02-07 |
| CO6190511A2 (es) | 2010-08-19 |
| US20090176804A1 (en) | 2009-07-09 |
| GT200900016A (es) | 2010-10-13 |
| NO20090862L (no) | 2009-02-24 |
| AR062051A1 (es) | 2008-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN08515A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| ECSP088813A (es) | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2 | |
| TNSN07098A1 (en) | 2,6- substituted -4- monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists | |
| TNSN07251A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| AU2012277802A8 (en) | Novel inhibitor compounds of phosphodiesterase type 10A | |
| CL2011000431A1 (es) | Compuestos derivados de 1-h-imidazo((4,5-c) o (1,2-a)-quinolina, (1,2,4)triazolo((4,3-a) o (1,5-c)-quinoxolina, entre otrois; composicion framaceutica, inhibidores de histamina, utiles en el tratamiento de pruritos, eczema, dermatitis, asma, rinitis, entre otros. | |
| MX2014003042A (es) | Nuevos derivados heterociclicos y sus usos. | |
| UY30917A1 (es) | Moduladores 2-aminopiridina del receptor histamina h | |
| CR20120331A (es) | Aminopirimidinas como inhibidores de syk | |
| ECSP088807A (es) | Tetrahidro-pirimidoazepinas como moduladores del potencial transitorio de receptor vaillinoide 1 (trpv1) | |
| CL2014001664A1 (es) | Compuestos derivados de 2-([1,4]dioxan-2-ilmetoxi)-6,7-dihidropirimido[6,1-a]isoquinolin-4-ona, antagonistas del receptor gpr84; composicion farmaceutica; metodo de tratamiento o profilaxis; y uso en el tratamiento o profilaxis de afecciones inflamatorias tales como artritis reumatoide, vasculitis, asma y psoriasis, entre otras. | |
| EA200802417A1 (ru) | Замещенные фенилуксусные кислоты как dp-2-антагонисты | |
| EA201990529A1 (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| ECSP088362A (es) | Sal de dihidrógeno fosfato de un antagonista del receptor de prostaglandina d2 | |
| EA200802415A1 (ru) | Замещенные фенилуксусные кислоты в качестве dp-2-антагонистов | |
| MX2009003100A (es) | Inhibidores de fosfodiesterasa tipo iv. | |
| GB201001070D0 (en) | Theraputic compounds and their use | |
| NO20084564L (no) | Stramme "Constrained" forbindelser som CGRP-reseptor antagonister | |
| DOP2009000009A (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
| MX2010008685A (es) | Farmacoforos duales-antagonistas muscarinicos de pde4. | |
| UA116480C2 (uk) | Похідна біфенілу та спосіб її одержання | |
| UA95303C2 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| NI201100014A (es) | Composiciones farmacéuticas basadas en antagonistas del receptor de quinina b2 y corticosteroides, y su uso. | |
| UY30505A1 (es) | Fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
| TR201003941A2 (tr) | Anti-alerjik ve anti-enflamatuar farmasötik bileşimler. |